TGFB1 and prostate cancer: The human prostate cancer cells LNCaP, lack TGF-β type II receptor and thus are refractory to effect of TGF-β1; genetically-engineered overexpression of the type II receptor restores sensitivity of LNCaP cells to TGF-β1 [26, 27].